DC Circ. Asks What's Wrong With Endo-Impax Deal
A D.C. Circuit panel questioned an attorney for the Federal Trade Commission on Monday about what makes a 2017 settlement between Endo Pharmaceuticals and Impax over an opioid medication that the...To view the full article, register now.
Already a subscriber? Click here to view full article